Načítá se...
Orphan Drug Pricing and Costs: A Case Study of Kalydeco and Orkambi
BACKGROUND: A common narrative is that high prices are necessary for “orphan drugs” because of the fewer patients. In the context of state health insurance systems, the high prices create significant challenges because of limited budgets. RESULTS: This study carefully examines both costs and revenue...
Uloženo v:
| Vydáno v: | Healthc Policy |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Longwoods Publishing
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7008693/ https://ncbi.nlm.nih.gov/pubmed/31629457 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12927/hcpol.2019.25937 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|